Eden Biodesign signs three contracts worth

Eden Biodesign, a provider of biopharmaceutical process development and cGMP manufacturing services, has recently signed three new contracts with a total initial value of nearly £3m (€3.5m).

Two are with new clients, one based in Asia and the other in Continental Europe. The third is for a new therapeutic with an existing UK client.

The contracts cover a combination of development and cGMP manufacturing services. Chief executive Dr Crawford Brown said he was pleased to announce the new contracts at a time when the industry is facing challenging market conditions.

‘We put our success down to our growing track record, particularly overseas, and we are considering accelerating our North American expansion plans,’ he said. ‘We are optimistic that we will be able to make further announcements of several more significant contract wins in the next few weeks and several exciting technology collaborations and partnerships in the coming months.’

Eden Biodesign’s recruitment continues as planned to support the growing client base and expanding project portfolio. The company is seeking scientists, engineers and specialists for key positions within the development and manufacturing teams.